Domača stran4AB • ETR
add
AbbVie Inc
Prejšnji trg. dan.
173,78 €
Dnevni razpon
172,96 € - 174,80 €
Letni razpon
125,50 € - 192,50 €
Tržna kapitalizacija
316,04 mrd. USD
Povprečni obseg
1,17 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NYSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 14,46 mrd. | 3,83 % |
Stroški poslovanja | 6,07 mrd. | 21,67 % |
Čisti dohodek | 1,56 mrd. | −12,20 % |
Čista dobičkovnost prihodkov | 10,80 | −15,43 % |
Earnings per share | 3,00 | 1,69 % |
EBITDA | 6,26 mrd. | −8,02 % |
Efektivna davčna stopnja | 24,95 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 7,28 mrd. | −45,18 % |
Skupna sredstva | 143,42 mrd. | 5,29 % |
Skupne obveznosti | 137,35 mrd. | 10,68 % |
Celoten lastniški kapital | 6,07 mrd. | — |
Shares outstanding | 1,77 mrd. | — |
Razmerje P/B | 50,96 | — |
Donosnost sredstev | 7,33 % | — |
Donosnost kapitala | 13,48 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,56 mrd. | −12,20 % |
Denar iz dejavnosti | 5,45 mrd. | −28,08 % |
Denar iz naložb | −8,26 mrd. | −2.137,40 % |
Denar iz financiranja | −3,07 mrd. | −15,45 % |
Neto sprememba denarnih sredstev | −5,87 mrd. | −229,70 % |
Prost denarni tok | 5,50 mrd. | −26,01 % |
Vizitka
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Datum ustanovitve
1. jan. 2013
Sedež organizacije
Spletno mesto
Zaposleni
50.000
